We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · December 01, 2022

Comparing Switch to Ocrelizumab, Cladribine, or Natalizumab After Fingolimod Treatment Cessation in Patients With MS

Journal of Neurology, Neurosurgery, and Psychiatry


Additional Info

Journal of Neurology, Neurosurgery, and Psychiatry
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis
J. Neurol. Neurosurg. Psychiatr. 2022 Dec 01;93(12)1330-1337, C Zhu, Z Zhou, I Roos, D Merlo, T Kalincik, S Ozakbas, O Skibina, J Kuhle, S Hodgkinson, C Boz, R Alroughani, J Lechner-Scott, M Barnett, G Izquierdo, A Prat, D Horakova, E Kubala Havrdova, R Macdonell, F Patti, SJ Khoury, M Slee, R Karabudak, M Onofrj, V Van Pesch, J Prevost, M Monif, V Jokubaitis, A van der Walt, H Butzkueven

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading